Sector: Health Care
Director information for MYRIAD GENETICS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Benjamin R. Wheeler | Chief Financial Officer | 42 | ["Bachelor of Science from Brigham Young University","Master of Accounting (MAcc) from Brigham Young University","served in various financial roles since December 2011"] | [] | 2026 |
| Brian J. Donnelly | Chief Commercial Officer | 43 | ["Chief Commercial Officer at Ancestry where led global commercial operations","Worldwide Leader, Diagnostics & Genomics at Amazon","Chief Commercial Officer of Codex DNA (now Telesis Bio)","Bachelor of Science in Business Administration from Elon University","Master of Business Administration and J.D. from Rutgers University"] | [] | 2026 |
| Colleen F. Reitan | Former Executive Vice President and President of Plan Operations and Chief Operating Officer, Health Care Services Corporation; Director | 66 | ["Over 35 years of experience in the managed care industry","Executive Vice President and President of Plan Operations at HCSC","Chief Operating Officer at HCSC","President and Chief Operating Officer at Blue Cross and Blue Shield of Minnesota","Expertise in reimbursement and managed care","Management experience in private companies","Experience serving as a director of a publicly-traded company","BoardDiversity","Finance and Accounting","Leadership","HealthcareIndustry","Research andDevelopment","Technology","PublicCompanyGovernance"] | ["AFC","NGC"] | 2026 |
| Dale Muzzey | Chief Scientific Officer | 46 | ["Chief Scientific Officer since April 2022","Interim Chief Scientific Officer at Myriad from January 2022 to April 2022","Senior Vice President, R&D from January 2022 to April 2022","Vice President, Bioinformatics from October 2019 to December 2021","Senior Director, Clinical Development from August 2018 to September 2019","Various positions at Myriad Women's Health from April 2014 to July 2018","Ph.D. in Biophysics from Harvard University","Bachelor of Arts degree in Biochemical Sciences from Harvard University"] | [] | 2026 |
| Dale Muzzey, Ph.D. | Chief Scientific Officer | [] | [] | 2026 | |
| Daniel M. Skovronsky M.D., Ph.D. | Director; President, Lilly Research Laboratories, Chief Scientific Officer at Eli Lilly and Company; President of Lilly Research Laboratories, President of Lilly Immunology, and Chief Scientific Officer | 52 | ["Finance and Accounting","Leadership","HealthcareIndustry","Research andDevelopment","M.D. from the Perelman School of Medicine at the University of Pennsylvania","Ph.D. in neuroscience from the University of Pennsylvania","B.S. in molecular biophysics and biochemistry from Yale University","Chief Executive Officer of Avid Radiopharmaceuticals Inc.","Extensive medical and scientific background","Significant business and management expertise in pharmaceutical industry","Background as a neuropathologist","Experience in neuroscience and diagnostics for neuropsychiatric conditions"] | ["CHCC","RPIC"] | 2026 |
| Heiner Dreismann Ph.D. | Director; Former Senior Executive, the Roche Group | 72 | ["Finance and Accounting","Leadership","HealthcareIndustry","Research andDevelopment","Technology","More than 20 years of business and managerial expertise at Roche","Expertise in developing and commercially launching diagnostic products","Experience in international markets, specifically in Europe","Deep scientific background and technical expertise","Experience in managing and serving as a director of several biotechnology companies"] | ["CHCC","RPIC"] | 2026 |
| Lee N. Newcomer M.D. | Director; Former Senior Vice President for Oncology and Genetics, Chief Medical Officer, UnitedHealth Group | 73 | ["Finance and Accounting","Leadership","HealthcareIndustry","Research andDevelopment","Technology","PublicCompanyGovernance","Managing his own consulting business","Held several senior executive roles at United Healthcare Group","Senior Vice President for Oncology and Genetics","Chief Medical Officer","Senior Vice President of Health Policy and Strategy","Worked for Vivius, Inc. as Executive Vice President and Chief Medical Officer","Previous board service at Park Nicollet Health Systems, including two years as Chairman","B.S. from Nebraska Wesleyan University","Master’s Degree in Healthcare Administration & Management from the University of Wisconsin, Madison","M.D. from the University of Nebraska, Omaha","Extensive reimbursement and managed care experience","Expertise in medical insurance industry","Experience in managed care and pharmaceutical industries"] | ["CHCC","RPIC"] | 2026 |
| Mark S. Davis | Senior Relationship and Growth Advisor at Cross Country Consulting and Former Senior Audit and Assurance Partner at Deloitte; Director | 63 | ["extensive expertise in financial accounting","public company reporting","experienced in management and executive leadership","background in corporate governance","experience in acquisitions and public company matters","BoardDiversity","Finance and Accounting","Leadership"] | ["AFC","NGC","audit committee","finance and investment committee"] | 2026 |
| Mark S. Verratti | Chief Operating Officer | 57 | ["Chief Operating Officer since April 30, 2025","Chief Commercial Officer from April 2022 to April 2025","President, Mental Health or President (Myriad Neuroscience) from August 2017 to April 2022","President of Myriad Autoimmune from May 2020 until September 2021","Senior Vice President and Chief Sales and Business Development Officer at Assurex Health from January 2016","Senior leadership positions with Cyberonics (now LivaNova) from 2005 to 2016","Led commercial teams with revenues approaching $500 million at Forest Pharmaceuticals","B.S. in Life Sciences with a minor in Physiology from The Pennsylvania State University"] | [] | 2026 |
| Paul M. Bisaro | Former Executive Chairman, Amneal Pharmaceuticals, Inc. and President and Chief Executive Officer, Impax Laboratories, Inc.; Director | 65 | ["More than 30 years of generic and branded pharmaceutical experience","Executive Chairman of Amneal Pharmaceuticals, Inc.","President and CEO of Impax Laboratories, Inc.","Executive Chairman of Allergan, plc","President and CEO of Actavis, plc","President, Chief Operating Officer of Barr Pharmaceuticals, Inc.","General Counsel of Barr","Senior Consultant with Arthur Andersen & Co.","Undergraduate degree in General Studies from the University of Michigan","J.D. from Catholic University of America","BoardDiversity","Finance and Accounting","Leadership","HealthcareIndustry","Technology"] | ["CHCC","RPIC"] | 2026 |
| Rashmi Kumar | Senior Vice President, Chief Information Officer, Medtronic plc; Director | 56 | ["Over 25 years of experience across various industries","Experience in healthcare, cybersecurity, and financial services","Held CIO and CTO leadership positions for several Fortune 50 companies","Expertise in digital transformation, AI/ML, data and analytics, and large-scale business process transformations","Bachelor’s degree in Metallurgical Engineering","MBA from the University of California, Irvine","BoardDiversity","Leadership","HealthcareIndustry","Technology"] | ["AFC","NGC"] | 2026 |
| Samraat S. Raha | President and Chief Executive Officer of Myriad Genetics, Inc.; President, CEO & Director; President and Chief Executive Officer and Director | 54 | ["Over 25 years of experience in the life sciences and diagnostics industry","Leadership roles in research and development, operations, and commercial functions","Served as Senior Vice President and President, Diagnostics and Genomics Group, of Agilent Technologies, Inc.","Experience leading global teams in diagnostics and genomics","BoardDiversity","Finance and Accounting","Leadership","HealthcareIndustry","Research andDevelopment","Technology","President and Chief Executive Officer at Myriad","Chief Operating Officer at Myriad","Senior Vice President and President, Diagnostics and Genomics Group at Agilent Technologies, Inc.","Senior Vice President, Strategy and Corporate Development at Agilent","Vice President, Global Marketing for Illumina, Inc.","Vice President and General Manager, Genomics Assays / NextGen qPCR for Life Technologies, Inc.","Degree in molecular and cell biology from the University of California, Berkeley","MBA from Santa Clara University"] | [] | 2026 |
| S. Louise Phanstiel | Former Senior Executive, Elevance Health, Inc. (formerly WellPoint, Inc.); Chair of the Board | 67 | ["extensive expertise in the healthcare industry","financial accounting, internal control and public company reporting expertise","business, financial, investment, and management expertise","institutional knowledge from tenure as a director","BoardDiversity","Finance and Accounting","Leadership","HealthcareIndustry","Research andDevelopment","Technology","PublicCompanyGovernance"] | ["AFC","NGC"] | 2026 |
